Table 1.
A summary of the main current PARPi combination clinical trials.
| Trial Name | Combination Therapy | Phase | Cohort | Start Completion Date |
Ref | |
|---|---|---|---|---|---|---|
| PARPi + Chemotherapy | (STUDY41) NCT01081951 |
Olaparib + Paclitaxel + Carbopatin | II | Platinum sensitive advanced ovarian cancer | 4 Feb 2010– 29 Dec 2023 |
[59] |
| PARPi + Immunotherapy | (TOPACIO) NCT02657889 |
Niraparib + Pembrolizumab | II | Platinum-resistance ovarian cancer (regardless BRCA or HRD status) or BRCA mutated metastatic TNBC | 15 Apr 2016– 17 Sep 2021 |
[66,67] |
| (ENGOT-OV44) NCT03602859 | Niraparib + Dostarlimab | III | Stage III or IV nonmucinous Epithelial ovarin cancer | 11 Oct 2018– 22 Jun 2026 |
[71] | |
| (MEDIOLA) NCT02734004 |
Olaparib + Durvalumab | II | gBRCAm platinum-sensitive ovarian cancer | 28 Oct 2018– 2026 |
[68] | |
| (OPEB-1) NCT04361370 |
Olaparib + Durvalumab + Bevacizumab | II | Platinum-sensitive recurrent BRCA wt ovarian cancer | 28 Oct 2020– Aug 2026 |
[70] | |
| (ATHENA) NCT03522246 | Rucaparib + Nivolumab | III | Newly diagonsed advanced (FIGO stage III-IV) epithelial ovarin cancer. Fallopian Tube diseases. | 14 May 2018– 30 Dec2030 |
[72] | |
| (DUO-O) NCT03737643 | Olaparib + Durvalumab | III | Newly diagonsed advanced ovarain cancer (Regardless BRCA status) | 4 Jan 2019– 25 May 2028 |
[73] | |
| NCT02849496 | Olaparib + Atezolizumb (Anti-PD-L1) | II | Locally advanced unresectable or metastatic non-HER2 positive breast cancer | 30 Mar 2017– 31 Aug 2023 |
[74] | |
| PARPi + Anti-angiogenic agents |
NCT01116648 | Olaparib + Cediranib | I/II | Relapsed Platinum sensitive high-grade or endometrioid ovarian cancer | 25 Mar 2010– 31 Oct 2018 |
[75] |
| (NRG-GY005) NCT02502266 |
Olaparib + Cediranib | II/III | Recurrent Platinum-resistant ovarian cancer, Fallopian Tube diseases. | 3 May 2016– 30 Jun 2024 |
[76] | |
| (PAOLA-1) NCT02477644 |
Olaparib + Bevacizumab | III | HRD positive high-grade ovarian cancer | 6 May 2015– 22 Mar 2022 |
[77,78,79] | |
| NCT02354131 | Niraparib + Bevacizumab | I/II | platinum-sensitive ovarian cancer | 15 Feb 2015– 15 Dec 2021 |
[80] | |
| PARPi + PI3K/AKT pathway inhibitors | NCT01623349 | Olaparib + Alpelisib | I | Platinum-resistant ovarian cancer or recurrent triple negative breast cancer (regardless BRCA or HRD status) | Sep 2012– Dec 2020 |
[81,82] |
| (EPIK-O) NCT04729387 |
Olaparib + Alpelisib | III | Platinum-resistant or refractory high-grade serious epithelial ovarian cancer (HGSOC) with BRCA wt. | 2 Jul 2021– 29 Jul 2025 |
[83] | |
| NCT02208375 | Olaparib + Vistusertib or Olaparib + Capivasertib | I/II | Recurrent endometrial, triple negative breast cancer or ovarian cancer | 11 Nov 2014– 20 Jun 2024 |
[84] | |
| NCT02338622 | Olaparib + Capivasertib | I | Platinum-resistant HGSOC (regardless BRCA or HRD status) | 31 Mar 2014– 21 Mar 2017 |
[85] | |
| NCT03586661 | Niraparib + Copanlisib | I | Recurrent high-grade serous or BRCA mutant ovarian cancer | 29 Apr 2019– 31 Dec 23 |
[86] | |
| PARPi + MAPK pathway inhibitors | NCT03162627 | Olaprib + Selumetinib | I/II | PARPi resistant ovarian cancer or Solid tumor with RAS pathway alteration | 4 Aug 2017– 30 Aug 2026 |
[87] |
| PARPi + Epigenetic drugs | NCT02878785 | Talazoparib + Decitabine | I/II | Acute Myeloid Leukemia | Aug 2016– 19 Nov 2020 |
[88] |
| NCT03742245 | Olaprib + Vorinostat | I | Relapsed metastatic breast cancer | 11 Jun 2019– 1 Sep 2024 |
[89] | |
| PARPi + DDR inhibitors | (CAPRI) NCT03462342 | Olaparib + Ceralasertib | II | Platinum-resistant HGSOC | 9 Mar 2018– 31 Dec 2023 |
[90] |
| NCT04267939 | Niraparib + Elimsertib | I | Recurrent advanced solid tumors and ovarian cancer. | 26 Feb 2020– 3 Mar 2025 |
[91] | |
| NCT03057145 | Olaparib + Prexasertib | I | BRCA mutant PARPi resistant HGSOC | 10 Mar 2017– 9 Jun 2021 |
[92] | |
| (EFFORT) NCT03579316 |
Olaparib + Adavosertib | II | PARPis resistant ovarian cancer | 7 Dec 2018– 30 Dec 2023 |
[93] | |
| NCT04991480 | Talozoparib + ART4215 | I/II | BRCA deficient breast cancer | 13 Sep 2021– Aug 2025 |
[94] |